The 2025 LogiPharma AI Report commissioned by LogiPharma revealed significant changes in the way pharmaceutical supply chains are adopting artificial intelligence, reflecting an industry in transition.
“In the last year, AI has progressed from pilots to practical deployment, with its application touching almost every area of the pharmaceutical supply chain,” says Ben Sharples, conference director of LogiPharma, owned and operated by Worldwide Business Research. “In the context of an increasingly unpredictable world, the industry is focused on ensuring it is braced for complexity, moving towards multi-layered resilience, prevention, prediction and contingency.”
Key takeaways:
· While investment remains consistent in real-time monitoring, especially in relation to the vulnerabilities of cold chain logistics, AI adoption is now strongest in predictive intelligence.
· The report found that 64% of respondents were evaluating blockchain and chain-of-custody technologies, alongside data analytics platforms (54%) and AI/ML for predictive risk alerts (53%), indicating a move toward a more proactive approach to resilience.
· Many respondents emphasize the potential of AI to strengthen patient outcomes, from personalized medicine delivery to faster recalls and counterfeit detection.
· Confidence and trust remain at the heart of industry discussion around the use of AI, with internal resistance (70%) representing one of the biggest challenges to wider implementation. Further barriers highlighted included regulatory uncertainty (58%) and a shortage of skilled talent or AI literacy (48%).
